With US and European long dated yields firming as investors reassess inflation risks, many cash rich businesses now look out of favour in share price terms. That gap between resilient cash generation and weaker market sentiment can be fertile ground for value hunters. This article focuses on the Undervalued Stocks Based On Cash Flows screener and highlights three stocks where discounted cash flow valuations suggest potential opportunity.
The three stocks below are only a sample. The full screen surfaces 41 more companies where discounted cash flow valuations flag similarly interesting cash generation stories that are not covered here. To identify and analyze those additional opportunities directly, head into the Undervalued Stocks Based On Cash Flows screener.
Coats Group is a long established supplier of threads, structural components and software to apparel and footwear brands worldwide, with large exposure to industrial customers in telecom and energy as well. The business currently leans on its Apparel division, which generates about $772.6 million in revenue, while Footwear contributes around $567.6 million and a segment adjustment of $256.2 million rounds out the reported mix. The company is valued by the market at roughly £1.6 billion.
Investors looking at Coats Group are really weighing a company that sits at the crossroads of rising demand for premium, sustainable materials and the need to improve returns from a relatively debt heavy balance sheet. Integration of OrthoLite and strong positions in athleisure and performance footwear give Coats access to higher margin, technology driven products, while recent results show revenue growth but some pressure on earnings per share and margins. On the other side of the ledger, high leverage, an unstable dividend record and a relatively new board introduce execution risk as the business pushes for cost savings and efficiency gains. The combination of a sizeable discount to analyst fair value estimates and a clear set of growth and efficiency targets is what makes this stock worth a closer look.
Coats Group’s push into higher margin footwear and performance materials is easy to focus on, yet the real story lies in how that growth compares with its leverage and cash engine. Put the pieces together with the 3 key rewards and 2 important warning signs
Coats Group and the other stocks in this article all surfaced from a single screener, but the real value for you comes from setting your own rules. Use our flexible Screener to blend filters such as valuation, future growth, balance sheet strength, risks and dividends, or start with one of our curated Investing Ideas.
Foresight Group Holdings is an asset manager focused on real assets and smaller company investing, running infrastructure, private equity, venture capital and listed funds across the UK, Europe and Australia. Most of its revenue currently comes from Real Assets at about £115 million, with Private Equity contributing roughly £50 million, and the UK remaining the core geography alongside a growing presence in Australia. The stock carries a market value of around £556 million.
Foresight Group Holdings may appeal to investors who are looking for a cash flow driven asset manager that combines growth ambitions with a focus on shareholder returns. The company is leaning into demand for renewable energy, infrastructure and private equity, with high quality earnings, profit margins reported near 28% and a P/E that has been cited as sitting below some estimates of fair value. At the same time, funding relies entirely on external borrowing and the business is closely tied to UK and European regulation, so policy shifts or weaker performance fees could be a risk. There is also an ongoing share buyback that is reducing the share count, which may make the company worth a closer look for some investors.
Foresight Group’s mix of real assets, private equity and buybacks hints at a story where cash flow strength and valuation may be out of sync. For the fuller picture, see the analysis report for Foresight Group Holdings
Diaceutics is a diagnostics commercialization company that helps pharma and biotech groups get precision medicines to the right patients using its DXRX data and analytics platform. The business currently generates about £38.4 million in revenue entirely from its Medical Labs & Research operations. The stock has a market value of around £122.2 million.
Diaceutics sits at the intersection of precision medicine and real world diagnostic data, which is why it stands out in a cash flow focused screen. The company has only recently turned a small profit, and analysts see earnings growth potential alongside revenue that is still tied mainly to one core segment. In addition, some estimates suggest the stock is priced below certain assessments of fair value, but it relies fully on external borrowing and operates with a relatively young, less independent board. For investors who can accept those governance and funding risks, the combination of earnings momentum and discounted valuation may merit closer attention.
Earnings momentum at Diaceutics and a valuation some investors may be overlooking create a powerful mix that the market has not fully priced in. See how the story changes when you factor in the analyst forecasts for Diaceutics
Fresh stock ideas can start moving fast once momentum builds and prices break out. Consider taking action while information is still under the radar for now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com